Drugs.com News (RSS) Feeds

The following RSS feeds are available:

• Daily MedNews
  Newsworthy items on a variety of topics related to the pharmaceutical industry and to the development, efficacy and safety of prescription and non-prescription drugs and supplements.
• News for Health Professionals
  Newsworthy items on a variety of topics related to the pharmaceutical industry and to the development, efficacy and safety of prescription and non-prescription drugs and supplements.
• FDA MedWatch Drug Alerts
  Latest alerts to consumers and health care providers warning of recently identified adverse effects associated with currently available drugs and supplements.
• New Drug Approvals
  Reports of FDA and international regulatory bodies' approvals of drugs currently in development.
• New Drug Applications
  Reports of new drug applications (or withdrawals of such applications) by pharmaceutical companies.
• Clinical Trial Results
  Latest updates on trial results from clinical trials currently in progress.

What are RSS feeds?

RSS is a format used to publish frequently updated content such as news feeds or blogs. RSS feeds allow you to get the latest headlines from a publisher as soon as they are published. You will need to have a feed reader installed in order to view RSS feeds correctly.

By subscribing to an RSS feed at Drugs.com, you can keep yourself updated with the latest news on drug applications and approvals, clinical trials, FDA Alerts, plus other drug-related topics.

Using Drugs.com RSS feeds on your website

We encourage the use of Drugs.com news feeds as part of a website, however, we do require that the proper format and attribution is used when Drugs.com News content appears. The attribution text should read "Drugs.com Headline News" or "Drugs.com Clinical Trial Results" as appropriate. You may not use any Drugs.com logo or other Drugs.com trademark.

We reserve the right to prevent the distribution of Drugs.com news content and Drugs.com does not accept any liability for its feeds. Please see the Terms and Conditions for full details.